תאריך רישום: October 29, 2012

מסלול הגשה: מולקולה חדשה

יצרן: CTS CHEMICAL INDUSTRIES LTD, ISRAEL

בעל רישום: CTS CHEMICAL INDUSTRIES LTD, ISRAEL

:ATC Code

תאריך רישום: December 9, 1992

מסלול הגשה: מולקולה חדשה

יצרן: GLAXO OPERATIONS UK LIMITED (TRADING AS GLAXO WELLCOME OPERATIONS)

בעל רישום: SANDOZ PHARMACEUTICALS ISRAEL LTD

J01DC02 :ATC Code

4.1 Therapeutic indications Zinnat is indicated for the treatment of the infections listed below in adults and children from the age of 3 months (see sections 4.4 and 5.1). • Acute streptococcal tonsillitis and pharyngitis. • Acute bacterial sinusitis. • Acute otitis media. • Acute exacerbations of chronic bronchitis. • Cystitis. • Pyelonephritis. • Uncomplicated skin and soft tissue infections. • Treatment of early Lyme disease. Consideration should be given to official guidance on the appropriate use of antibacterial agents.

תאריך רישום: December 9, 1992

מסלול הגשה: מולקולה חדשה

יצרן: GLAXO OPERATIONS UK LIMITED (TRADING AS GLAXO WELLCOME OPERATIONS)

בעל רישום: SANDOZ PHARMACEUTICALS ISRAEL LTD

J01DC02 :ATC Code

4.1 Therapeutic indications Zinnat is indicated for the treatment of the infections listed below in adults and children from the age of 3 months (see sections 4.4 and 5.1). • Acute streptococcal tonsillitis and pharyngitis. • Acute bacterial sinusitis. • Acute otitis media. • Acute exacerbations of chronic bronchitis. • Cystitis. • Pyelonephritis. • Uncomplicated skin and soft tissue infections. • Treatment of early Lyme disease. Consideration should be given to official guidance on the appropriate use of antibacterial agents.

תאריך רישום: December 9, 1992

מסלול הגשה: מולקולה חדשה

יצרן: GLAXO OPERATIONS UK LIMITED (TRADING AS GLAXO WELLCOME OPERATIONS)

בעל רישום: SANDOZ PHARMACEUTICALS ISRAEL LTD

J01DC02 :ATC Code

4.1 Therapeutic indications Zinnat is indicated for the treatment of the infections listed below in adults and children from the age of 3 months (see sections 4.4 and 5.1). • Acute streptococcal tonsillitis and pharyngitis. • Acute bacterial sinusitis. • Acute otitis media. • Acute exacerbations of chronic bronchitis. • Cystitis. • Pyelonephritis. • Uncomplicated skin and soft tissue infections. • Treatment of early Lyme disease. Consideration should be given to official guidance on the appropriate use of antibacterial agents.

תאריך רישום: September 2, 1993

מסלול הגשה: מולקולה חדשה

יצרן: FERRING INTERNATIONAL CENTER SA, SWITZERLAND

בעל רישום: FERRING PHARMACEUTICALS LTD

A07EC02 :ATC Code

4.1 Therapeutic indications Treatment of mild to moderate ulcerative colitis and Crohn’s disease.

תאריך רישום: November 30, 1982

מסלול הגשה: מולקולה חדשה

יצרן: MADAUS GMBH, GERMANY

בעל רישום: MEGAPHARM LTD

A12BA02 :ATC Code

4.1 Therapeutic indications To dissolve uric acid stones in the urinary tract. Prevention of further stone formation. Note: Product administration should be part of a general concept of metaphylaxis (i.e. diet, increased fluid uptake etc.). Mechanism of Action Uric acid is sparingly soluble or completely insoluble in solutions of greater acidity (i.e. pH below 6), and under these conditions, it forms crystals and in unfavourable circumstances may grow into stones. Uralyt-U action is based on the fact that it can stabilize the pH of urine within the correct pH range of 6.2 to 6.8. Thus Uralyt-U improves the solubility of uric acid and prevents the formation of uric acid crystals (stones) and also re-dissolves any crystals (stones) that are already present. Uralyt-U is free from carbohydrates and can therefore safely be taken by diabetics.